Antonio Gonzalez-Martin, MD

Antonio Gonzalez-Martin, MD, discusses the key safety findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Antonio Gonzalez-Martin, MD, discusses the rationale for targeting NaPi2b in ovarian cancer.

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.

Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.